VERAPAMIL HYDROCHLORIDE INJECTION USP SOLUTION
Country: Canada
Language: English
Source: Health Canada
Summary of Product characteristics
(SPC)
18-05-2021
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
VERAPAMIL HYDROCHLORIDE
Available from:
PFIZER CANADA ULC
ATC code:
C08DA01
INN (International Name):
VERAPAMIL
Dosage:
2.5MG
Pharmaceutical form:
SOLUTION
Composition:
VERAPAMIL HYDROCHLORIDE 2.5MG
Administration route:
INTRAVENOUS
Units in package:
2ML
Prescription type:
Prescription
Therapeutic area:
MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS
Product summary:
Active ingredient group (AIG) number: 0113846005; AHFS:
Authorization status:
APPROVED
Authorization date:
2004-04-08
Summary of Product characteristics
PRODUCT MONOGRAPH
PR
VERAPAMIL HYDROCHLORIDE INJECTION USP
2.5 MG/ML
2 mL Ampoules and Vials
Sterile Solution
_Antiarrhythmic_
Pfizer Canada ULC
17300 Trans-Canada Highway
Kirkland, Québec
H9J 2M5
Date of revision:
May 18, 2021
Control Number: 247539
_Product Monograph – _
_Pr_
_Verapamil Hydrochloride Injection USP _
_Page 2 of 46 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
3
SUMMARY PRODUCT INFORMATION
....................................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................
3
CONTRAINDICATIONS
...............................................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................................
4
ADVERSE REACTIONS
............................................................................................................
10
DRUG INTERACTIONS
............................................................................................................
14
DOSAGE AND ADMINISTRATION
........................................................................................
26
OVERDOSAGE
..........................................................................................................................
28
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................
30
STORAGE AND STABILITY
....................................................................................................
33
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................................ 33
PART II: SCIENTIFIC INFORMATION
..........................................................................................
34
PHARMACEUTICAL INFORMATION
....................................................................................
Read the complete document
